drugset / Trial / NCT00793975
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
Non-randomizedSingle-groupOpen-label
Summary
The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.
Timeline
- Start
- 2005-01
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramucirumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 13 mg/kg | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | 16 mg/kg | Intravenous |